IL111274A - Derivatives of 6-O-demethyl galanthamine - and pharmaceutical compositions containing them - Google Patents

Derivatives of 6-O-demethyl galanthamine - and pharmaceutical compositions containing them

Info

Publication number
IL111274A
IL111274A IL11127494A IL11127494A IL111274A IL 111274 A IL111274 A IL 111274A IL 11127494 A IL11127494 A IL 11127494A IL 11127494 A IL11127494 A IL 11127494A IL 111274 A IL111274 A IL 111274A
Authority
IL
Israel
Prior art keywords
hydrogen
derivatives
pharmaceutical compositions
compositions containing
alkylaminocarbonyl
Prior art date
Application number
IL11127494A
Other languages
English (en)
Other versions
IL111274A0 (en
Original Assignee
Hoechst Roussel Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Roussel Pharma filed Critical Hoechst Roussel Pharma
Publication of IL111274A0 publication Critical patent/IL111274A0/xx
Publication of IL111274A publication Critical patent/IL111274A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL11127494A 1993-10-15 1994-10-13 Derivatives of 6-O-demethyl galanthamine - and pharmaceutical compositions containing them IL111274A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/137,440 US6323195B1 (en) 1993-10-15 1993-10-15 Galanthamine derivatives as acetylcholinesterase inhibitors

Publications (2)

Publication Number Publication Date
IL111274A0 IL111274A0 (en) 1994-12-29
IL111274A true IL111274A (en) 2000-11-21

Family

ID=22477446

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11127494A IL111274A (en) 1993-10-15 1994-10-13 Derivatives of 6-O-demethyl galanthamine - and pharmaceutical compositions containing them

Country Status (23)

Country Link
US (2) US6323195B1 (fr)
EP (2) EP0653427B1 (fr)
JP (1) JP2664344B2 (fr)
KR (1) KR0169114B1 (fr)
CN (1) CN1039911C (fr)
AT (1) ATE212348T1 (fr)
AU (1) AU696249B2 (fr)
CA (1) CA2118174C (fr)
CZ (1) CZ287071B6 (fr)
DE (1) DE69429708T2 (fr)
DK (1) DK0653427T3 (fr)
EG (1) EG20472A (fr)
ES (1) ES2171428T3 (fr)
FI (1) FI108723B (fr)
IL (1) IL111274A (fr)
NO (1) NO310415B1 (fr)
NZ (1) NZ264683A (fr)
PL (1) PL177730B1 (fr)
PT (1) PT653427E (fr)
RO (1) RO114133B1 (fr)
RU (1) RU2114850C1 (fr)
TW (1) TW363969B (fr)
ZA (1) ZA948062B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
EP1133230A4 (fr) * 1998-11-23 2004-05-26 Bonnie M Davis Formulations de dosage d'inhibiteurs de l'acetylcholinesterase
DE69912311T2 (de) 1998-12-24 2004-07-29 Janssen Pharmaceutica N.V. Galantamin-zusammensetzung mit gesteuerter freisetzung
US8603546B2 (en) * 1999-01-11 2013-12-10 Herbaceuticals Inc. Herbal supplement for increased muscle strength and endurance for athletes
EP1150695B1 (fr) * 1999-01-11 2007-02-28 Atanas Russinov Djananov Complement alimentaire vegetal servant a ameliorer la resistance musculaire et l'endurance d'athletes
DK1086706T3 (da) * 1999-03-31 2004-03-08 Eisai Co Ltd Stabiliserede sammensætninger indeholdende nootropiske lægemidler
WO2001030318A1 (fr) * 1999-10-26 2001-05-03 Janssen Pharmaceutica N.V. Solution administree par voie orale contenant de la galanthamine et un edulcorant
EP1237524A4 (fr) * 1999-12-10 2004-06-30 Bonnie M Davis Analogues de galanthamine et de lycoramine, utilises en tant que modulateurs des recepteurs nicotiniques
CZ300160B6 (cs) 2000-03-31 2009-02-25 Sanochemia Pharmazeutika Aktiengesellschaft Deriváty galanthaminu, zpusob výroby techto derivátu, lécivo, které tyto deriváty obsahuje, použitítechto derivátu pro výrobu léciva, zpusob výroby tohoto léciva a zpusob separace (+)- a (-)-izomeruuvedených derivátu
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
CA2551946A1 (fr) * 2003-12-31 2005-07-21 Actavis Group Hf Formulations de galantamine
WO2005065662A1 (fr) * 2003-12-31 2005-07-21 Actavis Group Hf Formulations solides d'administration de galantamine
US20080045500A1 (en) * 2004-07-01 2008-02-21 Eisai R&D Management Co., Ltd. Nerve Regeneration Stimulator
US8632800B2 (en) * 2005-05-13 2014-01-21 Alza Corporation Multilayer drug delivery system with barrier against reservoir material flow
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
EP1777222A1 (fr) * 2005-09-22 2007-04-25 Galantos Pharma GmbH Inhibiteurs de la cholinesterase avec une perméabilité améliorée de la barrière ématoencéphalique pour le traitement de troubles cognitifs
ATE473219T1 (de) * 2005-09-22 2010-07-15 Galantos Pharma Gmbh Cholinerge enhancer mit verbesserter durchgängigkeit durch die blut-hirn-schranke zur behandlung von krankheiten, die mit kognitiven störungen einhergehen
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
US20070104771A1 (en) * 2005-09-23 2007-05-10 Jay Audett Transdermal galantamine delivery system
DK2137192T3 (da) 2008-04-14 2014-05-26 Neurodyn Life Sciences Inc Derivater af galantamin som prodrugs til behandling af humane hjernesygdomme
EP2456434A1 (fr) * 2009-07-23 2012-05-30 Shire LLC Promédicaments à base de l'acide aminé galantamine et de peptides et utilisations de ceux-ci
WO2013160728A1 (fr) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Composés à double ciblage pour le traitement de la maladie d'alzheimer
EP3628315A1 (fr) 2018-09-28 2020-04-01 Université de Caen Normandie Combinaison d'inhibiteur d'acétylcholinestérase et d'agoniste de récepteur de 5-ht4 comme agent neuroprotecteur dans le traitement de maladies neurodégénératives
CN113292420A (zh) * 2021-05-27 2021-08-24 神隆医药(常熟)有限公司 加兰他敏中间体原料2-溴-5-羟基-4-甲氧基苯甲酸回收方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL122665B1 (en) 1978-11-21 1982-08-31 Edinen Zentar Chim Process for preparing novel dienones of narvedine type and their derivatives
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
JP2755403B2 (ja) * 1987-05-04 1998-05-20 デイービス、ボニー アルツハイマー病の治療のための化合物
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
WO1992020327A1 (fr) 1991-05-14 1992-11-26 Ernir Snorrason Traitement des etats de fatigue a l'aide d'inhibiteurs de cholinesterase
US5153193A (en) 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US5231093A (en) * 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs

Also Published As

Publication number Publication date
EP1020470A2 (fr) 2000-07-19
PL305456A1 (en) 1995-04-18
EP0653427A1 (fr) 1995-05-17
EP1020470A3 (fr) 2000-07-26
RO114133B1 (ro) 1999-01-29
NZ264683A (en) 1998-03-25
FI944821A0 (fi) 1994-10-13
NO943893L (no) 1995-04-18
ATE212348T1 (de) 2002-02-15
CN1111245A (zh) 1995-11-08
AU7581494A (en) 1995-05-04
NO943893D0 (no) 1994-10-14
DE69429708D1 (de) 2002-03-14
KR950011443A (ko) 1995-05-15
DE69429708T2 (de) 2002-08-29
JP2664344B2 (ja) 1997-10-15
ES2171428T3 (es) 2002-09-16
PT653427E (pt) 2002-06-28
FI944821A (fi) 1995-04-16
EP0653427B1 (fr) 2002-01-23
IL111274A0 (en) 1994-12-29
US6323195B1 (en) 2001-11-27
CA2118174A1 (fr) 1995-04-16
CA2118174C (fr) 2000-01-18
PL177730B1 (pl) 2000-01-31
JPH07188240A (ja) 1995-07-25
US5777108A (en) 1998-07-07
FI108723B (fi) 2002-03-15
CN1039911C (zh) 1998-09-23
RU2114850C1 (ru) 1998-07-10
CZ287071B6 (en) 2000-08-16
TW363969B (en) 1999-07-11
EG20472A (en) 1999-05-31
RU94036448A (ru) 1996-09-10
NO310415B1 (no) 2001-07-02
AU696249B2 (en) 1998-09-03
CZ254694A3 (en) 1995-09-13
KR0169114B1 (ko) 1999-01-15
ZA948062B (en) 1995-06-06
DK0653427T3 (da) 2002-04-15

Similar Documents

Publication Publication Date Title
IL111274A (en) Derivatives of 6-O-demethyl galanthamine - and pharmaceutical compositions containing them
CA2092794A1 (fr) Naphtylalkylamines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GR3017243T3 (en) Antiemetic and migraine suppressing heterocyclic compounds and pharmaceutical compositions containing them.
ZA948060B (en) Galanthamide derivatives,a process for their preparation and their use as medicaments
AU1614492A (en) New peptide compound and a process for the preparation thereof
AU5595490A (en) Antispasmodic agents
AU6582394A (en) Novel bisoxadiazolidine derivative
HU9501664D0 (en) New cephem compounds
HU9502627D0 (en) Antitumor compositions and methods of treatment
MY109729A (en) Benzofuranylimidazole derivatives, a process for the preparation and therapeutical compositions containing the same
AU7458894A (en) 1,5-benzodiazepine derivatives useful as cck or gastrin antagonists
TW254937B (en) Benzocycloheptene derivative and process for preparation thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
HCA Change of name of proprietor(s) after amalgamation
FF Patent granted
KB Patent renewed
EXP Patent expired